Company Lexagene Holdings Inc Toronto S.E.
Equities
WEY
CA52886L1031
Biotechnology & Medical Research
Business Summary
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Genetic Analyzer
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +21.70% |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +21.70% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jack Regan
CEO | Chief Executive Officer | - | 07-04-25 |
Jeffrey Mitchell
DFI | Director of Finance/CFO | - | 18-02-28 |
Steven Armstrong
COO | Chief Operating Officer | - | 20-03-23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph P. Caruso
BRD | Director/Board Member | 65 | 18-06-17 |
Jack Regan
CEO | Chief Executive Officer | - | 07-04-25 |
Tom Slezak
BRD | Director/Board Member | - | 16-10-11 |
Jane Sykes
BRD | Director/Board Member | - | 21-11-14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 140,740,255 | 115,621,362 ( 82.15 %) | 0 | 82.15 % |
Company contact information
Lexagene Holdings, Inc.
500 Cummings Center Suite 4550
01915, Beverly
+800 215 1824
http://www.lexagene.comSector
1st Jan change | Capi. | |
---|---|---|
-16.10% | 11.41B | |
+67.65% | 3.81B | |
-14.31% | 2.16B | |
-26.03% | 1.56B | |
+36.95% | 1.19B | |
-2.40% | 760M | |
-19.00% | 506M | |
-38.57% | 444M | |
+13.72% | 339M |